Article
Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.
Antimicrobial agents and chemotherapy - 1 Nov 1997
Back N K, Berkhout B
Abstract excerpt
The nucleoside drug lamivudine (3TC) triggers the selection of resistant forms of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) with a substitution of amino acid 184Met. The 3TC-resistant RT enzymes 184Val and 184Ile exhibit a processivity defect in in vitro assays th...
Topics
- Cells, Cultured
- Deoxyribonucleotides
- Drug Resistance, Microbial
- HIV Reverse Transcriptase
- HIV-1
- Lamivudine
- Mutation
- Reverse Transcriptase Inhibitors
- Virion
- Virus Replication